Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia [Phase 3]

View source ↗

Summary

Phase 3 trial assessing efficacy and safety of Risperidone in Situ Microparticle (ISM) for acute schizophrenia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Risperidone in Situ Microparticle (ISM) (risperidone)

Snippet

Sponsor: Rovi Pharmaceuticals Laboratories | Conditions: Acute Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2022-02-04